Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer drug olaparib, potentially expanding its benefits beyond patients with BRCA-related tumors. The combination is already being tested in human clinical trials after showing strong immune-boosting and anticancer effects in preclinical studies.
Source: ScienceDaily — Health & Medicine
